[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
Light-to-moderate Alcohol Consumption and Progressive NAFLD Light-to-moderate Alcohol Consumption and Progressive NAFLD
This systemic review aimed to determine the impact of light-to-moderate alcohol use on the progression of NAFLD to NASH, fibrosis, cirrhosis and hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2023 Category: Pharmaceuticals Source Type: news
Adjuvant Combo May Change Practice in High-Risk Liver Cancer
(MedPage Today) -- ORLANDO -- For the first time, adjuvant therapy has improved recurrence-free survival (RFS) after surgery or ablation for hepatocellular carcinoma (HCC), the most common type of liver cancer, according to the randomized IMbrave050... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 17, 2023 Category: Gastroenterology Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
Immunotherapy in HCC: Influence of Underlying Liver Disease Immunotherapy in HCC: Influence of Underlying Liver Disease
A new review looks at the potential impacts of liver disease on the efficacy of immunotherapy in patients with hepatocellular carcinoma.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
ChatGPT May Help Patients Better Understand Cirrhosis, Liver Cancer
(MedPage Today) -- Generative artificial intelligence (AI) chatbot ChatGPT may be helpful for delivering some medical information to patients with cirrhosis or hepatocellular carcinoma (HCC), according to an analysis of AI-generated answers to... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 6, 2023 Category: Gastroenterology Source Type: news
Chemoprevention of HCC With Statins, Aspirin and Metformin Chemoprevention of HCC With Statins, Aspirin and Metformin
A new meta-analysis examines the question of whether statins, aspirin and metformin are chemoprotective against the development of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 28, 2023 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
NHS launches new initiative to check for cancer in high-risk communities
A new initiative to deliver on-the-spot liver scans to check for cancer in high-risk communities has been rolled out as part of a major NHS drive to catch more cancers earlier and save lives. The programme identifies those at risk of the most common form of liver cancer, hepatocellular carcinoma, which makes up 85% of... Read moreThe post NHS launches new initiative to check for cancer in high-risk communities appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - March 15, 2023 Category: Nursing Authors: Wiliam Hunter Tags: Latest news Source Type: news
SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape | Science Signaling
Antitumor immunity against liver cancer is impaired by SUMOylation of intracellular IL-33. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - March 14, 2023 Category: Science Source Type: news
Liver Fibrosis Among Relatives of Mexican Americans With HCC Liver Fibrosis Among Relatives of Mexican Americans With HCC
Mexican Americans are disproportionately affected by obesity and metabolic syndrome. Does hepatocellular carcinoma increase the familial risk for liver fibrosis in this population?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Hepatocellular Carcinoma and Hepatitis C Virus Treatments Hepatocellular Carcinoma and Hepatitis C Virus Treatments
This review elucidates the pathogenesis of chronic HCV-induced hepatocellular carcinoma, discussing the relationship between hepatic carcinogenesis and viral eradication by antivirals.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 27, 2023 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Tenofovir vs Entecavir After Treatment for HBV-related HCC Tenofovir vs Entecavir After Treatment for HBV-related HCC
This review compared the efficacy of entecavir and tenofovir for reducing the risk of recurrence and mortality after curative therapy for HBV-related hepatocellular carcinoma.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 20, 2023 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
